|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||13.75 - 13.75|
|52 Week Range||6.98 - 32.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 15, 2018 - May 21, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.00|
Understanding how Synairgen plc (AIM:SNG) is performing as a company requires looking at more than just a years’ earnings. Today I will run you through a basic sense check toRead More...
If you are a shareholder in Synairgen plc’s (AIM:SNG), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...
AstraZeneca, struggling with loss of patents on blockbusters like cholesterol pill Crestor, reported another quarter of falling drug sales on Thursday as it awaits pivotal clinical trial data that may revive its fortunes. Chief Executive Pascal Soriot believes 2017 will mark the trough for the British group, as it starts to put generic losses behind it and builds up sales of recently launched and experimental cancer medicines. Industry analysts, on average, had forecast revenue of $5.4 billion and earnings of 82 cents, according to Thomson Reuters data.
SOUTHAMPTON, England, March 10, 2017 /PRNewswire/ -- - Phase I c linical trial s cheduled to start in H2 2017 Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces ...